Literature DB >> 18991752

Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview.

Sónia Correia1, Cristina Carvalho, Maria S Santos, Raquel Seiça, Catarina R Oliveira, Paula I Moreira.   

Abstract

Type 2 diabetes is a major health problem associated with excess mortality and morbidity. Vascular complications are one of the most serious consequences of this disorder. Moreover, type 2 diabetes is also a risk factor for cerebral complications, including cognitive impairment and dementia. However, it has been shown that tight glycemic control contributes to reduce the incidence of diabetes-associated complications. Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity. This review is mainly devoted to describe the mechanisms of action underlying the antidiabetic effects of metformin. Furthermore, we will present evidence for the protective effects of metformin against diabetes-associated complications mainly cerebral and vascular complications. Finally, we will describe the few known side effects associated to this antidiabetic agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991752     DOI: 10.2174/138955708786369546

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  31 in total

1.  Impact of metformin use on the prognostic value of lactate in sepsis.

Authors:  Jeffrey P Green; Tony Berger; Nidhi Garg; Alison Suarez; Yolanda Hagar; Michael S Radeos; Edward A Panacek
Journal:  Am J Emerg Med       Date:  2012-03-16       Impact factor: 2.469

2.  Restoration of Rostral Ventrolateral Medulla Cystathionine-γ Lyase Activity Underlies Moxonidine-Evoked Neuroprotection and Sympathoinhibition in Diabetic Rats.

Authors:  Mohamed A Fouda; Shaimaa S El-Sayed; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2017-11-13       Impact factor: 4.030

Review 3.  Metformin use among individuals at risk for type 2 diabetes.

Authors:  Lewis H Kuller
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

4.  Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene.

Authors:  Lucie Krausova; Lucie Stejskalova; Hongwei Wang; Radim Vrzal; Zdenek Dvorak; Sridhar Mani; Petr Pavek
Journal:  Biochem Pharmacol       Date:  2011-09-06       Impact factor: 5.858

5.  Effects of sericin on the testicular growth hormone/insulin-like growth factor-1 axis in a rat model of type 2 diabetes.

Authors:  Cheng-Jun Song; Zhen-Jun Yang; Qi-Feng Tang; Zhi-Hong Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

6.  Metformin Reduces Lipogenesis Markers in Obese Mice Fed a Low-Carbohydrate and High-Fat Diet.

Authors:  Karla Nayara de Oliveira Santana; Deborah Farias Lelis; Keila Lopes Mendes; Jamille Fernandes Lula; Alanna Fernandes Paraíso; João Marcus Oliveira Andrade; John David Feltenberger; Junio Cota; Diego Vicente da Costa; Alfredo Mauricio Batista de Paula; André Luiz Sena Guimarães; Sérgio Henrique Sousa Santos
Journal:  Lipids       Date:  2016-11-01       Impact factor: 1.880

7.  Increased susceptibility to amyloid-β toxicity in rat brain microvascular endothelial cells under hyperglycemic conditions.

Authors:  Cristina Carvalho; Paige S Katz; Somhrita Dutta; Prasad V G Katakam; Paula I Moreira; David W Busija
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 8.  Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Drugs       Date:  2012-01-01       Impact factor: 9.546

Review 9.  Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

10.  In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.

Authors:  Qingqiong Luo; Dan Hu; Shuiqing Hu; Ming Yan; Zujun Sun; Fuxiang Chen
Journal:  BMC Cancer       Date:  2012-11-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.